Thrombin and fibrinolysis

Chest

Volumn 124, Issue 3 SUPPL., 2003, Pages 33S-39S

  Nesheim, Michael ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Bleeding; Coagulation; Fibrinolysis; Plasmin; Thrombin; Thrombin activatable fibrinolysis inhibitor; Thrombomodulin; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9; CARBOXYPEPTIDASE B; ENZYME PRECURSOR; FIBRIN; FIBRINOGEN; FIBRINOPEPTIDE A; FIBRINOPEPTIDE B; MELAGATRAN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SERINE PROTEINASE INHIBITOR; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR;

ANGINA PECTORIS; ARTERY THROMBOSIS; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING; CARDIOVASCULAR SYSTEM; CHIMPANZEE; CHROMOSOMAL LOCALIZATION; CORONARY ARTERY THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; HEMOPHILIA; HUMAN; LIVER CIRRHOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RABBIT; REVIEW; THROMBOSIS;

EID: 0141707850     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.124.3_suppl.33S     Document Type: Article

References (55)

1. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30:10363-10370
2. Mann KG, Bovill EG, Krishnaswamy S. Surface-dependent reactions in the propagation phase of blood coagulation. Ann N Y Acad Sci 1991; 614:63-75
3. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78:3114-3124
4. Irigoyen JP, Munoz-Canoves P, Montero L, et al. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 1999; 56:104-132
5. Giles AR, Nesheim ME, Herring SW, et al. The fibrinolytic potential of the normal primate following the generation of thrombin in vivo. Thromb Haemost 1990; 63:476-481
6. Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000; 1477:349-360
7. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271:16603-16608
8. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 20:2511-2518
9. Wang W, Boffa MB, Bajzar L, et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273:27176-27181
10. Nesheim M, Wang W, Boffa M, et al. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997; 78:386-391
11. Collen D, Lijnen HR. Molecular and cellular basis of fibrinolysis. In: Hoffman R, Benz E, Shattil SJ, et al, eds. Hematology: basic principles and practice. New York, NY: Churchill Livingstone, 1991; 1232-1242
12. Eaton DL, Malloy BE, Tsai SP, et al. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266:21833-21838
13. Boffa MB, Wang W, Bajzar L, et al. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998; 273:2127-2135
14. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. j Biol Chem 1995; 270:14477-14484
15. Henry M, Aubert H, Morange PE, et al. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97:2053-2058
16. Marx PF, Bouma BN, Meijers JC. Role of zinc ions in activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry 2002; 41:1211-1216
17. Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry 1995; 34:5811-5816
18. Wang W, Hendriks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269:15937-15944
19. Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989; 162:933-939
20. Vanhoof G, Wauters J, Schatteman K, et al. The gene for human carboxypeptidase U (CPU): a proposed novel regulator of plasminogen activation; maps to 13q14.11. Genomics 1996; 38:454-455
21. Boffa MB, Reid TS, Joo E, et al. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry 1999; 38:6547-6558
22. Mosnier LO, Buijtenhuijs P, Marx PF, et al. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101:4844-4846
23. Anderson GM, Shaw AR, Shafer JA. Functional characterization of promoter elements involved in regulation of human B beta-fibrinogen expression: evidence for binding of novel activator and repressor proteins. J Biol Chem 1993; 268: 22650-22655
24. Wang W, Nagashima M, Schneider M, et al. Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. J Biol Chem 2000; 275:22942-22947
25. Kokame K, Zheng X, Sadler JE. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J Biol Chem 1998; 273:12135-12139
26. Hall SW, Nagashima M, Zhao L, et al. Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains. J Biol Chem 1999; 274:25510-25516
27. Bell R, Stevens WK, Jia Z, et al. Fluorescence properties and functional roles of tryptophan residues 60d, 96, 148, 207, and 215 of thrombin. J Biol Chem 2000; 275:29513-29520
28. Schneider M, Nagashima M, Knappe S, et al. Amino acid residues in the P6-P′3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation. J Biol Chem 2002; 277: 9944-9951
29. Glaser CB, Morser J, Clarke JH, et al. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity: a potential rapid mechanism for modulation of coagulation. J Clin Invest 1992; 90:2565-2573
30. Boffa MB, Bell R, Stevens WK, et al. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 2000; 275:12868-12878
31. Schneider M, Boffa M, Stewart R, et al. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277:1021-1030
32. Marx PF, Hackeng TM, Dawson PE, et al. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J Biol Chem 2000; 275:12410-12415
33. Morange PE, Henry M, Frere C, et al. Thr325IIe polymorphism of the TAFI gene does not influence the risk of myocardial infection. Blood 2002; 99:1878-1879
34. Brummel KE, Paradis SG, Butenas S, et al. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100:148-152
35. Butenas S, van 't Veer C, Cawthern K, et al. Models of blood coagulation. Blood Coagul Fibrinolysis 2000; 11(suppl 1):S9-S13
36. Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88:3815-3823
37. Mosnier LO, Lisman T, van den Berg HM, et al. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001; 86:1035-1039
38. Von dem Borne PA, Bajzar L, Meijers JC, et al. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99:2323-2327
39. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95:2855-2859
40. Yano Y, Kitagawa N, Gabazza EC, et al. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab 2003; 88:736-741
41. Morange PE, Juhan-Vague I, Scarabin PY, et al. Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. Thromb Haemost 2003; 89:554-560
42. Watanabe R, Wada H, Watanabe Y, et al. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 2001; 104:1-6
43. Meijers JC, Oudijk EJ, Mosnier LO, et al. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 2000; 108:518-523
44. Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001; 85:667-670
45. Lisman T, Leebeek FW, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121:131-139
46. Lisman T, Mosnier LO, Lambert T, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002; 99:175-179
47. Redlitz A, Nicolini FA, Malycky JL, et al. Inducible carboxypeptidase activity: a role in clot lysis in vivo. Circulation 1996; 93:1328-1330
48. Mattsson C, Bjorkman JA, Abrahamsson T, et al. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran). Thromb Haemost 2002; 87:557-562
49. Klement P, Liao P, Bajzar L. An inhibitor of activated TAFI enhances thrombolysis. Blood 1998; 92:1967-1975
50. Nagashima M, Werner M, Wang M, et al. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000; 98:333-342
51. Refino CJ, Schmitt D, Pater C, et al. Carboxypeptidase inhibitor markedly improves the potency of tPA in vivo. Fibrinolysis Proteolysis 1998; 12:29
52. Nagashima M, Yin ZF, Zhao L, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109:101-110
53. Skidgel RA. Human carboxypeptidase N: lysine carboxypeptidase. Methods Enzymol 1995; 248:653-663
54. Lee CD, Mann KG. Activation/inactivation of human factor V by plasmin. Blood 1989; 73:185-190
55. Samis JA, Ramsey GD, Walker JB, et al. Proteolytic processing of human coagulation factor IX by plasmin. Blood 2000; 95:943-951